Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Syros Pharmaceuticals excels in heme programs and strategic collaborations

Syros Pharmaceuticals demonstrated strong performance in heme programs, financial resilience, and strategic collaborations, despite challenges in expenses and net losses.
The company's focus on upcoming catalysts and clinical program advancements presents opportunities for growth and innovation in the competitive biopharmaceutical landscape.
Navigating challenges in trial protocols and financial management, Syros Pharmaceuticals aims to leverage strengths in regulatory designations and partnerships for sustainable growth.

Syros Pharmaceuticals reports Q1 progress in key programs and trials

Syros Pharmaceuticals' Q1 2023 performance reflects ongoing investments in late-stage clinical programs amid revenue generation.
The company's focus on key therapeutic areas and proactive approach to trial protocols position it for potential clinical and regulatory milestones.
While facing challenges in financial performance and the need for clarity on trial-related matters, Syros Pharmaceuticals maintains a solid cash position and promising opportunities ahead.

Syros Pharmaceuticals reports Q2 progress in clinical trials and challenges

Syros Pharmaceuticals' Q2 performance reflects a focus on advancing innovative therapies for MDS and AML amid significant R&D investments.
The company faces challenges in managing financials, decision-making timelines, and balancing investments with revenue generation.
Opportunities lie in the potential of tamibarotene, strategic partnerships, and upcoming data readouts to drive future growth and value creation.

Syros Pharmaceuticals advances tamibarotene for hematologic malignancies under new CEO

Syros Pharmaceuticals is strategically advancing tamibarotene for hematologic malignancies under new leadership, with a strong financial performance in the third quarter. While facing challenges in meeting efficacy data expectations, the company has opportunities to address unmet needs in AML and MDS, positioning itself for growth.

Syros Pharmaceuticals reports positive trial results and secures $45M financing

Syros Pharmaceuticals showcased strong performance in clinical trials and financial management in Q4 2023.
While facing challenges in regulatory aspects and profitability, the company is well-positioned for growth.
Opportunities lie in upcoming trial data, product launches, and strategic initiatives for revenue expansion.
Overall, Syros Pharmaceuticals remains optimistic about its future prospects and market positioning.

Syros Pharmaceuticals advances tamibarotene with FDA Fast Track Designation

Syros Pharmaceuticals showcased progress in clinical development programs, particularly with tamibarotene, and secured FDA Fast Track Designation for AML treatment. Despite no revenue in Q1 2024, the company's financial position remains stable with $108.3 million in cash and extended financial flexibility. Challenges include revenue impact from terminated agreements and the need to navigate market competition.

Syros Pharmaceuticals reports Q2 loss, eyes market expansion opportunities

Syros Pharmaceuticals showcased progress on tamibarotene trials with positive results in MDS and AML.
Financial performance in Q2 2024 reflected a net loss but maintained solid cash reserves for operations.
Analyst inquiries and executive insights highlighted strategic focus on pivotal studies and commercialization plans.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EyePoint Pharmaceuticals

Verastem

If the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside. To clarify, the ideas present tremendous risks.

Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Karen Hunady - Director of Investor Relations & Corporate Communications Nancy Simonian - President & Chief Executive Officer Conley Chee - Chief Operating Officer David Roth - Chief Medical Officer Jason Haas - Chief Financial Officer Conference Call Participants Ted Tenthoff - Piper Sandler Phil Nadeau - TD Cowen Operator Good morning and welcome to Syros Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] This call is being webcast live on the Investors and Media section of Syros' website at www.syros.com.

Syros Pharmaceuticals, Inc. (SYRS) Q3 2023 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update. “Syros is entering the fourth quarter well-positioned for its next phase of growth. We are laser-focused on advancing tamibarotene for the frontline treatment of hematologic malignancies an.

Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 14, 2023 to report its third quarter 2023 financial results and provide a corporate update. To access the live conference call, please dial (888) 259-6580 (domestic) or (416) 764-8624 (intern.

Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

Syros Pharmaceuticals shares dropped on Monday after a series of shakeups at the biotech company. The firm is saying goodbye to its CEO, Nancy Simonian, who will retire by the end of the year, and chief scientific officer Eric Olsen.

Syros Pharmaceuticals undergoes leadership shakeup, workforce reduction

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced a strategic realignment to prioritize key development and pre-launch activities to advance tamibarotene for the frontline treatment of higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Also today, Syros announced the retirement as Chief Executive Offi.

Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Karen Hunady - Director, IR and Corporate Communications Nancy Simonian - President and CEO David Roth - CMO Jason Haas - CFO Conley Chee - CCOO Conference Call Participants Ted Tenthoff - Piper Sandler Phil Nadeau - TD Cowen Operator Good morning, and welcome to Syros Pharmaceuticals' Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen only mode.

Syros Pharmaceuticals, Inc. (SYRS) Q2 2023 Earnings Call Transcript

Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $1.30 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $5.40 per share a year ago.

Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended June 30, 2023 and provided a corporate update. “In the second quarter and recent months, we continued to focus on clinical execution, enrolling patients in our SELECT-AML-1 and SELECT-MDS-1 trials and advancing both studies toward data readou.

Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 8, 2023 to report its second quarter 2023 financial results and provide a corporate update. To access the live conference call, please dial (888) 886-7786 (domestic) or (416) 764-8658 (internat.

Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

Pfizer

Syros Pharmaceuticals said on Friday Pfizer will terminate a license deal between the companies related to the development of novel therapies for two blood disorders.

Pfizer to end license deal with Syros for blood disorder therapies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the Sidoti June 2023 Virtual Small-Cap Conference. Management will also be available for one-on-one meetings. Details are as follows: Sidoti June 2023 Virtual Small-Cap Conference Date: Th.

Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced new clinical data from the Phase 1/1b clinical trial evaluating SY-5609, its highly selective and potent inhibitor of CDK7, in patients with relapsed/refractory pancreatic ductal adenocarcinoma (PDAC), HR+ breast cancer and other solid tumors. The data will be presented in two pos.

Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $4 per share a year ago.

Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2023 and provided a corporate update. “In 2023, we are focusing on clinical execution, with the goal of delivering tamibarotene and SY-2101 as new standards of care for the frontline treatment of hematologic malignancies,” said Nanc.

Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities 2023 Life Sciences Conference. Management will also be available for one-on-one meetings. Details are as follows: JMP Securities 2023 Life Sciences Conference Date: Tu.

Syros to Present at JMP Securities 2023 Life Sciences Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its first quarter 2023 financial results and provide a corporate update. To access the live conference call, please dial (888) 886-7786 (domestic) or (416) 764-8658 (internati.

Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Karen Hunady - Director-Investor Relations & Corporate Communications Nancy Simonian - Chief Executive Officer David Roth - Chief Medical Officer Jason Haas - Chief Financial Officer Conference Call Participants Philip Nadeau - Cowen and Company Mark Breidenbach - Oppenheimer Jason Butler - JMP Securities Operator Good morning, and welcome to Syros Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Syros Pharmaceuticals, Inc. (SYRS) Q4 2022 Earnings Call Transcript

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update.

Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming investor conferences in March. Management will also be available for one-on-one meetings.

Syros to Participate in Upcoming Investor Conferences in March

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update.

Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023

Final results from pivotal study SELECT-MDS-1, using Tamibarotene for the treatment of patients with newly diagnosed high-risk MDS that have RARA gene overexpression, expected Q3 of 2024. The global myelodysplastic syndrome market is expected to reach $5.6 billion by 2032; 50% of high-risk MDS patients have RARA expression.

Syros: Multiple Shots On Goal In Blood Cancer Space

Syros Pharmaceuticals, Inc. (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength?

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene for the treatment of higher-risk myelodysplastic syndrome (HR-MDS). Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with azacitidine for the treatment of newly diagnosed HR-MDS patients with RARA gene overexpression.

News for Syros Pharmaceuticals Stock (SYRS)